The addition of mycophenolate (MMF) to corticosteroid yields improved outcomes over corticosteroid alone as a first-line therapy for immune thrombocytopenia (ITP), according to results of the UK-based FLIGHT trial presented at the ASH 2020 Meeting. “Mycophenolate seems to approximately halve the risk of refractory or relapsed ITP,” said Dr Charlotte Bradbury of the University of ...
Mycophenolate offers better results than corticosteroid alone in ITP
By Dave Levitan
10 Dec 2020